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O desenvolvimento de métodos rápidos e eficazes para a identificação de novas moléculas 
bioativas é fundamental para o processo de descoberta e planejamento de fármacos. A integração 
de um sistema de cromatografia liquida de alta eficiência (CLAE), com biorreatores como 
fase estacionária (IMER) é uma estratégia atrativa e versátil para a triagem de coleções de 
compostos visando à identificação de novos agentes terapêuticos. Os parâmetros cinéticos da 
enzima imobilizada gliceraldeído-3-fosfato desidrogenase (GAPDH) de Trypanosoma cruzi e 
humana foram determinados (T. cruzi: KMG3P = 0.50 mmol L-1; KMNAD+ = 0.67 mmol L-1; humana: 
KM
G3P
 = 3.7 mmol L-1; KMNAD+ = 0.75 mmol L-1) e comparados com aqueles observados em solução 
(T. cruzi: KMG3P = 0.42 mmol L-1; KMNAD+ = 0.26 mmol L-1; humana: KMG3P = 0.16 mmol L-1; 
KM
NAD+
 = 0.18 mmol L-1). Os resultados indicaram uma diminuição na afinidade das enzimas 
imobilizadas, entretanto, os elementos estruturais necessários para o processo de reconhecimento 
molecular e atividade biológica permaneceram inalterados, aumentando a estabilidade das enzimas. 
Além disso, a análise estrutural forneceu dados moleculares importantes envolvidos nos efeitos da 
imobilização sobre as interações entre ligante e receptor e, consequentemente, sobre a atividade 
enzimática e parâmetros cinéticos.
The development of fast and reliable methods for the identification of new bioactive 
compounds is of utmost importance to boost the process of drug discovery and development. 
Immobilized enzyme reactors (IMERs), integrated with high performance liquid chromatography 
(HPLC), are attractive and versatile tools for screening collections consisting of natural products 
and synthetic small molecules. Standard kinetic parameters of the immobilized enzyme 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from both Trypanosoma cruzi de and 
human have been determined (T. cruzi: KMG3P = 0.50 mmol L-1; KMNAD+ = 0.67 mmol L-1; humana: 
KM
G3P
 = 3.7 mmol L-1; KMNAD+ = 0.75 mmol L-1), and comparisons of these values with those of the 
parasite and human free enzymes  indicate a decrease in the affinity for the immobilized system  
(T. cruzi: KMG3P = 0.42 mmol L-1; KMNAD+ = 0.26 mmol L-1; humana: KMG3P = 0.16 mmol L-1; 
KM
NAD+
 = 0.18 mmol L-1).  Interestingly, despite the kinetic differences between the two systems, 
the immobilized GAPDHs retained the required structural requirements for molecular recognition 
and biological activity, increasing the stability the enzyme. In the present work, we described 
an integrated structural analysis which has provided important insights into the molecular basis 
underlying the effects of immobilization on the ligand-receptor interactions and consequent 
enzymatic activity and kinetics parameters.
Keywords: immobilized enzymes reactors, enzymes, kinetic parameters, structural analysis, 
drug design
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Introduction 
The current drug discovery paradigm strongly relies 
on knowledge, creativity, innovation, and a combination 
of modern strategies and technologies.1 Immobilized 
enzyme reactors (IMERs) have recently been considered 
with great interest by the scientific community as a 
screening method capable of identifying hits and lead 
candidates.2 The use of IMERs, integrated with high 
performance liquid chromatography (HPLC), represents 
an attractive and versatile approach for screening either 
highly diverse or focused collections of small molecule 
compounds for binding to major molecular drug targets. 
This method allows the rapid screening of both natural 
products and synthetic compounds for biological activity, 
enabling more compounds to be tested against a particular 
or a set of macromolecular targets. Other advantages of 
the IMER system include its high stability, reliability 
and high performance, which are important components 
for increasing the accuracy and reproducibility of the 
experimental measurements while minimizing the costs 
and time of data collection and analysis when compared to 
standard kinetic enzymatic assays in free solution.3 Several 
studies of enzyme immobilization methods in biocatalysis 
have been reported, emphasizing the applicability 
and importance of this technology in biotechnology 
and drug design.3-5 For instance, (i) on-line synthesis; 
(ii) identification of metabolites; (iii) purification and 
determination of chiral molecules; and (iv) identification 
of new hits and leads. Particularly, immobilized enzymes 
can be implemented as an alternative high-throughput 
screening (HTS) method aimed at identifying novel drug 
candidates for the treatment of several life-threatening 
diseases.6-8
Neglected tropical diseases are widely distributed 
throughout the tropical and subtropical regions of the 
world, with significant social and economic impact.9,10 
Chagas’ disease, caused by the parasite Trypanosoma 
cruzi, is a parasitic infection widespread in the Americas, 
from the great lakes of North America to Southern 
Patagonia, with devastating consequences in terms of 
human morbidity and mortality.11 Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, EC 1.2.1.12), a key 
enzyme involved in the glycolytic pathway of T. cruzi, 
catalyzes the reversible oxidative phosphorylation of 
the substrate glyceraldehyde-3-phosphate (GAP) to 
1,3-diphosphoglycerate in the presence of the cofactor 
NAD+ and inorganic phosphate.12,13 Crystallographic and 
molecular modeling studies revealed significant structural 
differences between the parasite enzyme and its human 
homologue that can be explored for the development 
of selective inhibitors with therapeutic potential.14-22 
Considering the fact that selectivity is an essential 
property in the design of novel chemotherapeutic agents, 
we have recently developed robust and efficient IMERs 
for the GAPDHs from both T. cruzi and human.23,24 
The kinetics parameters are important to probe 
the influence of the immobilization on the enzyme’s 
structure,25,26 given that immobilization may impact the 
binding affinity of substrates and inhibitors and thus, the 
catalytic properties.27-29
As part of our research program aimed at understanding 
the mechanisms underlying affinity and selectivity, we have 
evaluated the kinetic parameters of the free and immobilized 
GAPDHs from T. cruzi and human. Subsequently, we have 
correlated the kinetic data with the three-dimensional (3D) 
structures available in protein databank (PDB) in order to 
identify the structural elements related to the differences 
observed. This integrated analysis provided important 
insights into the molecular basis underlying the effects of 
immobilization on the kinetic parameters. 
Experimental
Materials
Recombinant T. cruzi GAPDH was prepared and 
purified according to the previously reported procedure.30 
Human GAPDH crystalline derived from human 
erythrocyte, D-glyceraldehyde-3-phosphate (G3P) and 
β-nicotinamide adenine dinucleotide (NAD+) were 
purchased from Sigma Aldrich (St. Louis, MO, USA). 
Buffer components and all chemical materials used during 
the immobilization procedure were of analytical grade 
supplied by Sigma or by Merk (Darmstdt, Germany). All 
solvents were HPLC grade purchased from J.T. Baker 
(Phillipsburg, USA). All experiments used water purified 
with a Millipore Milli-Q system (Millipore, São Paulo, 
Brasil). The mobile phases were prepared daily. Fused-
silica capillary for electrophoresis (0.375 mm×0.10 mm) 
used to immobilize the enzyme and prepare the IMERs 
was purchased from Polymicro Technologies (Phoenix, 
AZ, USA). The Luna - octyl silica (10 mm, 100 Å) and 
the spherex- Diol OH silica (10 µm, 100 Å) were supplied 
by Phenomenex (Torrance, CA, USA). Before their use 
for HPLC analysis, the buffers solutions were filtered 
through cellulose nitrate membrane filters (0.45 mm) 
purchased from Phenomenex. Dialysis and concentration 
of enzymatic solution was carried out using a 30 mL 
Amicon concentrator (Millipore, Billerica, MA) and an 
Eppendorf centrifuge (Eppendorf Instruments, Enfield, 
USA).
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Methods
Immobilization of GAPDH onto capillary
T. cruzi and human GAPDHs were covalently 
immobilized onto an electrophoresis fused-silica capillary 
based on the procedures previously described.23,24 
Chromatographic and spectrophotometric systems
Two modular HPLC systems were setup in order to carry 
out the on-line studies. The chromatographic experiments 
were performed using a Shimadzu HPLC system (Shimadzu, 
Kyoto, Japan), which consisted of the two LC 10 AD VP 
pumps with one of the pumps having a valve FCV-10AL for 
selecting solvent, a UV-Vis detector (SPD-M10AV VP), an 
autosampler equipment with a 500 L loop (SIL 10 AD VP). 
The column containing the immobilized GAPDH enzyme 
(GAPDH-IMER) was coupled on-line to an octyl column 
(Luna-Phenomenex®, 100 Å, 10 mm, 10 cm × 0.46 mm i.d.). 
A six-way switching sample-valve Valco Nitronic 7000 EA 
(Supelco, St. Louis, MO, USA) was used to connect the 
two columns. The data were acquired on a Shimadzu 
SCL 10 AVP system interface with a computer equipped 
with Shimadzu-Lc solutions (Lcsolution 2.1) software 
(Shimadzu, Kyoto, Japan). The free enzymes were evaluated 
using a Shimadzu (Shimadzu, Kyoto, Japan) UV- 1650 PC 
spectrophotometer, with a computer equipped with a UV 
Probe (Kinetics) software version 1.10 for data collection. 
Spectrometric determinations of free GAPDHs were carried 
out using a Cary 100 Bio UV/V equipped with a Peltier-
thermostated multicell changer and a temperature controller.
Kinetics measurements of the free GAPDH 
All enzymatic assays were carried out in triplicate at 
25 °C. The enzymatic activities of soluble T. cruzi and human 
GAPDHs were evaluated by measuring the biochemical 
reduction of NAD+ to NADH (λ = 340 nm).30,31 Enzymatic 
activity was calculated from the initial slope of the curve 
obtained during 30 s of the reaction. NAD+ concentrations 
varied from 0.25 to 15 mmol L-1 and G3P concentrations 
from 0.15 and 15 mmol L-1. The parameters for NAD+ were 
determined under saturating conditions of G3P (800 µmol L-1), 
whereas the parameters for G3P were determined under 
saturating concentrations of NAD+ (800 µmol L-1). 
T. cruzi GAPDH
The 500 µL reaction mixture contained 445 mL 
of triethanolamine buffer (100 mmol L-1, pH 7.5, 
containing 1.0 mmol L-1 EDTA, 1.0 mmol L-1 PMSF, 
1.0 mmol L-1 β-mercaptoethanol), 15 mL of 30 mmol L-1 
Na2HAsO4•7H2O, 5 mL of NAD+, 30 mL de G3P. The 
reaction was initiated with the addition of the 5 mL enzyme 
(20 nmol L-1).
Human GAPDH
The 500 µL reaction mixture contained 460 mL 
of Tris-HCl buffer (50 mmol L-1, pH 8.6, containing 
1.0 mmol L-1 β-mercapthoetanol,  30 mmol L-1 
Na2HAsO4•7H2O, 1.0 mmol L-1 EDTA) 30 mL de G3P, 
5 mL NAD+. The reaction was initiated with the addition 
of the 5 mL enzyme (20 nmol L-1). 
Kinetics studies of the immobilized enzyme
The enzymatic activity of GAPDH-IMERs format was 
evaluated employing the multidimensional chromatographic 
system.23,24 Kinetic studies were performed under saturating 
conditions for NAD+ or G3P as detailed below. 
T. cruzi GAPDH-IMER
Solutions with NAD+ concentrations ranging from 0.10 
to 12.5 mmol L-1 and G3P concentrations between 0.10 
and 12.5 mmol L-1 were injected in duplicate. The kinetic 
constants for NAD+ were determined under saturating 
conditions of G3P (7.5 mmol L-1) while the parameters for 
G3P were determined at saturating concentrations of NAD+ 
(10 mmol L-1). Samples were injected in duplicate (15 µL, 
flow rate: 0.05 mL min-1; injection time: 2 min) following 
the chromatographic conditions previously specified.23
Human GAPDH-IMER 
Solutions with NAD+ concentrations ranging from 0.10 
to 20 mmol L-1 and G3P concentrations between 0.20 and 
20 mmol L-1 were injected in duplicate. The parameters 
for NAD+ were determined under saturating conditions 
of G3P (7.5 mmol L-1) while the parameters for G3P 
were determined at saturating concentrations of NAD+ 
(10 mmol L-1). Samples were injected in duplicate (15 µL; 
flow rate: 0.05 mL min-1; injection time: 2 min) following 
the chromatographic conditions previously specified.24
Data analysis
SigmaPlot software was used to determine the 
kinetic parameters for the studied systems. Non-linear 
regression analysis using five independent measurements 
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(mean ± S.D.) of initial velocity for substrate or cofactor 
was employed for kinetic evaluation (analyses based on 15 
points collected experimentally). 
Results and Discussion 
Kinetics parameters
The kinetic parameters for the free enzyme in 
solution and for the immobilized format were evaluated 
for the GAPDH substrate and cofactor, G3P and NAD+, 
respectively. The kinetic parameters of the T. cruzi 
(TcGAPDH) and human (HuGAPDH) GAPDHs were 
determined by systematic variation of the concentrations of 
the substrate (G3P or NAD+), while all other components 
were kept at constant concentrations. Stock solutions 
of substrate and cofactor were prepared at the highest 
experimentally reasonable concentration. Serial dilutions 
were then made from these stocks to obtain a curve of initial 
velocity versus substrate concentration (Michaelis-Menten 
plot). Substrate and cofactor concentrations required for 
15-85% enzymatic activity of GAPDH were used for 
kinetic evaluation. Nonlinear curve-fitting regression 
analysis was applied in order to determine the KM and 
VMAX values from the collected data of five independent 
experiments. The results are presented in Table 1, Figure 1 
and Figure 2.
The covalent immobilization of the GAPDH (T. cruzi 
and human) retained the enzymatic activity. As can be seen 
in Figure 1 and 2, the immobilized enzymes are capable of 
catalyzing the oxidative phosphorylation of the G3P in the 
presence of the cofactor NAD+. The reaction rate increases 
as a function of the cofactor concentration and tends to 
proceed to nearly complete conversion of substrate to 
product (data not shown). Additionally, the IMER systems 
exhibited highly similar kinetic parameters compared 
to those observed previously,23,24 thereby confirming the 
accuracy and reproducibility of the developed methods, 
which are essential elements to be addressed.
The KM values of the immobilized parasite enzyme 
(TcGAPDH-IMER) for both G3P and NAD+ are in good 
agreement with the data obtained for the free enzyme 
in solution (Table 1). The kinetic data indicate that 
immobilization onto capillary has a small effect on the 
TcGAPDH binding affinity for both substrate and cofactor. 
The KM values for the G3P and NAD+ are, respectively, 
2.6 and 1.2-fold higher than those observed for the free 
enzyme. Similarly, the VMAX parameter is 1.7-fold higher in 
the IMER format for the cofactor and virtually equivalent 
for the substrate (Table 1). Conversely, the immobilization 
procedure has a substantial effect on the HuGAPDH kinetic 
parameters. As can be observed in Table 1, a significant 
difference in the KM values for NAD+ and G3P occurred 
for the immobilized and free HuGAPDH systems. A higher 
KM value means lower affinity between the enzyme and 
substrate, which could be due to the introduction of steric 
hindrance created by the support towards the active site, as 
well as by the lack of sufficient enzyme flexibility for binding 
of the natural ligands during catalysis.27,29,32 Additionally, 
the VMAX values evaluated for HuGAPDH-IMER are 
approximately 6-fold higher than those exhibited for the 
free enzyme (Table 1). Although it is difficult to estimate 
the extent of the derivatization with glutaraldehyde onto the 
capillary, the increase in the VMAX values might be attributed 
to the presence of a large number of potential reaction sites 
for covalent coupling with the protein, thereby increasing the 
amount of active enzyme immobilized onto the capillary.3,29 
Alternatively, the larger number of lysine residues may allow 
for double binding on the same tetramer, which would affect 
the extensive dynamics of the enzyme, required for catalysis. 
Table 1. Determination of the kinetic parameters KM and VMAX for the free and immobilized human and T. cruzi GAPDHs by nonlinear curve-fitting 
regression analysis*
GAPDH G3P NAD+
KM (mmol L-1) VMAX (mmol L-1 min-1) KM (mmol L-1) VMAX (mmol L-1 min-1)
T. cruzi 
free 0.42 ± 0.02 3.9 ± 0.1 0.26 ± 0.02 3.7 ± 0.1
IMER 0.50 ± 0.05 4.3 ± 0.3 0.67 ± 0.08 6.4 ± 0.1
IMER/free 1.2 1.1 2.6 1.7
Human
free 0.16 ± 0.02 5.0 ± 0.2 0.18 ± 0.01 4.2 ± 0.1
IMER 3.7 ± 0.29 33 ± 7 0.75 ± 0.04 24 ± 0.2
IMER/free 23 6.6 4.1 5.7
*The data shown are representative of five independent experiments (mean ± S.D.).
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Structural analysis of TcGAPDH and HuGAPDH
The activity retained after the immobilization procedure 
indicates that both systems conserved the structural 
requirements necessary for molecular recognition and 
binding of the both substrate and cofactor. Based on 
these important results, a detailed structural analysis of 
the enzymes was carried out aimed at understanding the 
factors that determine individual responses to the kinetic 
parameters upon immobilization on GAPDHs. 
The primary sequence alignment revealed that both 
GAPDHs share approximately 50% sequence identity, 
with most of the conserved residues lying on motifs that 
are required for ligand recognition and catalysis (Figure 3). 
Despite the low sequence identity, the tertiary and quaternary 
structures of the enzymes are significantly similar (Figure 4). 
GAPDH is a homotetramer of molecular mass approximately 
150 kDa whose subunits are related to each other by a 
222 non-crystallographic symmetry (Figure 4). Each subunit 
consists of two folding domains. The cofactor binding site 
(Figure 5) is situated in a cleft formed by the NAD+ binding 
domain (N-terminal domain), which has an α/β folding 
pattern characteristic of the Rossmann fold, with a central 
parallel β-sheet covered on both sides by α-helices. The 
substrate binding site (Figure 5) is located in the catalytic 
domain (C-terminal domain) which folds into an eight-
stranded antiparallel β-sheet and two α-helices.30,33 In order 
to carry out its biochemical role, the substrate and cofactor 
must bind to the enzyme active site in a coordinated fashion 
that induces a remarkable conformational change of the 
NAD+ binding domain along with the shift of several side 
chains close to the active site.34,35
The immobilization methodology employed in this 
work relies on a pre-activated fused silica capillary with 
glutaraldehyde, which reacts with primary amino groups 
on the enzyme structure (i.e., Schiff base formation).23,24 
Thus, lysine residues play a crucial role in this process 
with an intensive multipoint covalent attachment being 
Figure 1. Michaelis-Menten kinetics for T. cruzi GAPDH in free solution and IMER format. 
Structural Insights into the Molecular Basis Responsible for the Effects of Immobilization J. Braz. Chem. Soc.1850
Figure 2. Michaelis-Menten kinetics for human GAPDH in free solution and IMER format. 
Figure 3. Sequence alignment of T. cruzi and human GAPDH. The numbers above the sequences refer to the parasite enzyme. Conserved residues between 
species are outlined and lysine residues are depicted in blue (online version). 
highly dependent on the amount of amino groups available 
on the protein surface.36 It is worth noting that the lysine 
amino acids are not involved in the biochemical reaction 
catalyzed by GAPDH.34,37 According to the sequence 
alignment, TcGAPDH has 88 lysine residues per tetramer, 
whereas the human homologue exhibits 104 residues, most 
of them located in non-conserved regions (Figure 3). The 
larger number of lysine residues on HuGAPDH suggests 
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a higher probability of covalent attachments, which might 
lead to an enhanced amount of immobilized enzyme 
onto capillary. This finding is in good agreement with the 
increased VMAX values observed for the HuGADH-IMER 
(Table 1). Accordingly, the distribution of the lysine residues 
throughout the structures of the GADPH enzymes indicates 
that the differences observed in the kinetic parameters for 
the IMER systems are most probably related to the number 
and position of the residues modified during immobilization.
A close inspection of the Tc and HuGAPDH three-
dimensional (3D) structures revealed that the vast majority 
of the lysine residues lye on the solvent accessible surface, 
therefore, far enough away from the substrate and cofactor 
binding sites (Figure 5). However, there are two conserved 
lysine residues (Lys201 and Lys209 in TcGAPDH; 
and Lys186 and Lys194 in HuGAPDH) located in the 
proximity of the binding sites of the enzymes. On one 
hand, the TcGAPDH-Lys201 and HuGAPDH-Lys186 
are buried into the binding pockets (Figure 5), suggesting 
that the reactive center of those residues might not be 
in a permissible distance for a covalent attachment. On 
the other hand, immobilization through the TcGAPDH-
Lys209 or HuGAPDH-Lys194 residues is likely to affect 
the access to the active site, leading to electrostatic and 
steric hindrances, thereby accounting in part for the higher 
KM values observed in both IMER systems. Particularly, 
the human homologue shows two non-conserved lysine 
residues (Lys84 and Lys107) located in key positions very 
close to the binding site entrance (Figure 5). Although 
they are not directly involved in the catalytic (enzymatic) 
reaction, structural modification of these residues by Schiff 
base reaction introduces additional bulky elements that 
could obstruct the access to the active site, which might 
contribute to the substantial decrease in the affinity of the 
HuGAPDH-IMER for its substrate and cofactor.
Conformational changes
Proteins can exist in multiple conformational states.38,39 
It has been shown that upon binding of the ligand 
(e.g., substrate, cofactor, inhibitor), the resulting protein-
ligand complex assumes a new conformation that has lower 
energy than the protein alone. This mechanism allows 
the ligand to first gain access to the binding site and as a 
next step to be surrounded by groups on the enzyme. It is 
generally accepted that the open domain conformation of 
the enzyme is favored in the absence of the ligand, and the 
closed stabilized by the presence of the ligand.38
Figure 4.  Tertiary (A) and quaternary (B) structures of the TcGAPDH 
(PDB ID, 1QXS) and HuGAPDH (PDB ID, 1ZQN). *rmsd (root mean 
square deviation for Cα)
Figure 5. (A) Cartoon representation of GAPDH tertiary structure 
highlighting the substrate (cyan-online version) and cofactor (purple-
online version) binding sites (PDB ID, 1QXS). Protein residues involved 
in the binding sites as well as the substrate analog (S70, light blue-online 
version) and cofactor (NAD+, light pink-online version) molecules are 
indicated as stick model. (B) Connolly surface of GAPDH highlighting 
the substrate (cyan-online version) site and cofactor (purple-online 
version) binding sites.
Figure 6. Upper panel: Connolly surface of the TcGAPDH (PDB ID, 
1QXS) and HuGAPDH (PDB ID, 1ZQN) quaternary structures. Lower 
panel: close inspection of the lysine residues close to the binding site 
of the TcGAPDH (B/C subunits) and HuGAPDH (P/Q subunits). The 
B/C and P/Q subunits are equivalent subunits between TcGAPDH and 
HuGAPDH, respectively. The lysine residues are indicated in cyan (online 
version carbon atoms) and blue (online version nitrogen atoms), and the 
active sites are colored in yellow (online version).
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Conformational studies performed on the GAPDH 
structures from several sources identified two preferred 
conformational states: NAD+-free (open form) and NAD+-
bound (closed form).40-42 These investigations revealed 
significant protein mobility concomitant with cofactor 
binding. The NAD+ binding domain rotates 3 to 4 degrees 
relative to the catalytic domain (hinge movement). The 
induced conformational change can be described as an 
overall rigid-body rotation of the NAD+ binding domain 
followed by the translation movement of several structural 
elements. The effect of this rotation is to shield the active 
site from solvent in the closed form, thereby favoring the 
catalytic reaction.40 In light of this, the covalent linked 
lysine residues adjacent to the hinge region may restrict 
the flexibility of the structural components involved in the 
catalytic mechanism. This structural restriction can further 
contribute to the decrease in affinity of the GAPDH-IMER 
systems. Since HuGAPDH exhibits a higher number of 
lysine residues in the hinge region (aa 23-150),43 the 
effect of immobilization on this homologue might be 
enhanced, which is in agreement with our experimental 
data (Table 1).
Conclusion
The knowledge of the 3D organization is very 
helpful in the analysis of the kinetic constants and 
structural differences allowing an integrated study of 
the experimental and theoretical results in immobilized 
and free solution enzymatic systems. IMERs are highly 
versatile tools in drug discovery allowing the screening 
of a variety of small molecule compounds (from natural 
products or synthetic libraries) for binding to major 
molecular drug targets. High stability and reliability are 
other advantages of the IMER systems, allowing accuracy 
and reproducibility of the experimental measurements. 
Although the immobilization procedure has caused a 
decreased in the affinity of both substrate and cofactor 
for the GAPDH enzymes, the structural determinants 
for molecular recognition were not affected. The results 
indicate that after the immobilization, the G3P and NAD+ 
binding sites are available for the catalytic process to take 
place. In summary, the combined kinetic and structural 
analysis provided useful insights into the molecular 
determinants related to the effects of immobilization on 
the enzymatic activity.
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Figure S1. Stereoview of the binding site residues from (A) TcGAPDH and (B) HuGAPDH. The lysine residues are indicated in cyan (carbon atoms) and 
blue (nitrogen atoms), and the active sites are colored in yellow.
